Silva Giselle de Barros, Mendes Adriana Pessoa, de Macedo Mariana Petaccia, Pinto Clóvis Antônio Lopes, Gibbons Ivana Lameiras, Duprat Neto João Pedreira
AC Camargo Cancer Center, SP, BR.
An Bras Dermatol. 2015 May-Jun;90(3 Suppl 1):242-6. doi: 10.1590/abd1806-4841.20153841.
Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.
维莫非尼是一种用于治疗转移性和不可切除黑色素瘤的V600E突变型BRAF蛋白的选择性抑制剂。临床试验表明，接受维莫非尼治疗的患者总生存期和无进展生存期有所延长。然而，治疗期间皮肤不良事件很常见。我们报告了5例BRAF V600E阳性的转移性黑色素瘤患者，接受维莫非尼治疗及其皮肤不良事件。皮肤科医生和肿瘤学家需要意识到这种越来越多地用于黑色素瘤治疗的药物可能引起的皮肤变化。治疗期间对患者进行监测对于早期治疗皮肤不良事件、改善生活质量和坚持治疗很重要。
